Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Next Previous
Trial Profile

Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Bumetanide; Deuterium oxide; Glucose
  • Indications Heart failure; Type 2 diabetes mellitus
  • Focus Proof of concept; Therapeutic Use
  • Acronyms EMPA

    • Most Recent Events

    • 01 Feb 2024 Results assessing whether Empagliflozin caused substantial redistribution of intrarenal sodium delivery and reabsorption, providing mechanistic substrate to explain some of the benefits of this class, published in the Journal of the American Society of Nephrology
    • 22 May 2020 According to a Daxor Corporation media release, Daxors BVA-100 blood volume measurement device was used to determine the primary endpoint of this study.
    • 15 May 2020 Results (blood volume outcome data ) published in the Circulation Journal.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top